Nivolumab/hyaluronidase

"Opdivo Qvantig" redirects here; not to be confused with Opdivo.

Nivolumab/hyaluronidase
Combination of
NivolumabProgrammed death receptor-1-blocking antibody
HyaluronidaseEndoglycosidase
Clinical data
Trade namesOpdivo Qvantig
Other namesNivolumab/hyaluronidase-nvhy
AHFS/Drugs.comOpdivo-qvantig
MedlinePlusa625029
License data
Routes of
administration		Subcutaneous injection
ATC code
  • None
Legal status
Legal status

Nivolumab/hyaluronidase, sold under the brand name Opdivo Qvantig, is a fixed-dose combination anti-cancer medication used for the treatment of various forms of cancer. Nivolumab/hyaluronidase contains nivolumab, a programmed death receptor-1 (PD-1)–blocking monoclonal antibody; and hyaluronidase, an endoglycosidase. It is given by subcutaneous injection.

Nivolumab/hyaluronidase was approved for medical use in the United States in December 2024.

This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.